27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Erasca Inc (NASDAQ:ERAS) said that due to a lack of clinical activity, it would not continue exploring ERAS-007 combined with palbociclib in patients with RAS-mutated gastrointestinal malignancies or ERAS-007 combined with osimertinib in patients with post-osimertinib EGFR-mutated non-small cell lung cancer.
- The company will deprioritize certain discovery programs: ERAS-9 (SOS1), ERAS-11 (MYC), and ERAS-2/3 (RAS switch-II groove targeting), but is pursuing other promising research approaches to target RAS mutations beyond G12C.
- Erasca also announced preliminary Phase 1b data for ERAS-007 in patients with metastatic BRAF V600E-mutated (BRAFm) colorectal cancer (CRC).
- 50% (3/6) response rate, including two confirmed partial responses (cPR) and one unconfirmed partial response (uPR), and a 67% (4/6) disease control rate (DCR) was observed at the highest dose of ERAS-007 tested (100 mg BID-QW).
- Across all dose levels in EC-naïve response evaluable patients, 38% (3/8) response rate, including two cPRs and one uPR, and 63% (5/8) DCR.
- ERAS-007 + EC was generally well tolerated, with primarily low-grade treatment-related adverse events (TRAEs) at all combination doses. No Grade 4 or 5 TRAEs were observed.
- One dose-limiting toxicity was reported for ERAS-007 100 mg BID-QW + EC (Grade 3 macular edema)
- Price Action: ERAS shares closed at $3.30 on Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!